This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-04. Anything still debated is marked as such rather than presented as settled.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Nicotinic acid has the formula C6H5NO2 and belongs to the group of the pyridinecarboxylic acids. As the precursor for nicotinamide adenine dinucleotide and nicotinamide adenine dinucleotide phosphate, it is involved in DNA repair. Extra-terrestrial nicotinic acid has been found in carbonaceous chondrite meteorites and in sample-returns from the asteroids 162173 Ryugu and 101955 Bennu.
== Fame == Vanity Fair name her one of the "50 French Women who made 2020", alongside Adèle Haenel and Virginie Despentes. Technikart named her as one of the "100 who can save 2021". Website Brut named her on a panel of "31 who made 2022 happen". Étienne gained wider media attention in early 2023, when she allegedly had an affair with dancer and choreographer Benjamin Millepied, who was married to actress Natalie Portman at the time. On March 8, 2024, it was announced that Portman and Millepied had divorced.
Based on a precautionary approach, WHO recommends focusing control of exposure on preventing inhalation exposure with the aim of reducing it as much as possible (strong recommendation, moderate-quality evidence). WHO recommends reduction of exposures to a range of MNMs that have been consistently measured in workplaces especially during cleaning and maintenance, collecting material from reaction vessels and feeding MNMs into the production process. In the absence of toxicological information, WHO recommends implementing the highest level of controls to prevent workers from any exposure. When more information is available, WHO recommends taking a more tailored approach (strong recommendation, moderate-quality evidence). WHO recommends taking control measures based on the principle of hierarchy of controls, meaning that the first control measure should be to eliminate the source of exposure before implementing control measures that are more dependent on worker involvement, with PPE being used only as a last resort. According to this principle, engineering controls should be used when there is a high level of inhalation exposure or when there is no, or very little, toxicological information available. In the absence of appropriate engineering controls PPE should be used, especially respiratory protection, as part of a respiratory protection programme that includes fit-testing (strong recommendation, moderate-quality evidence).
Missions played a variety of roles in the postwar world: the mission in San Francisco assisted participants in the meeting that established the United Nations, the mission in Europe acquired European publications for the Library of Congress and other American libraries, and the mission in Japan aided in the creation of the National Diet Library.
== Therapeutic relevance == Fundamental discoveries uncovering the biology of ferroptosis and translational studies showing the disease relevance of ferroptosis have motivated efforts to develop therapeutics that modulate ferroptosis. For example, Kojin Therapeutics and PTC Therapeutics are exploring ferroptosis modulation for treatment of cancer and Friedrich's ataxia. Ferroptosis has been implicated in a range of different diseases including cancer, ischemia/reperfusion injury (IRI), inflammation, neurodegeneration, and kidney injury.
Sources: en.wikipedia.org
== Structural properties == Traditionally, PPII has been considered to be relatively rigid and used as a "molecular ruler" in structural biology, e.g., to calibrate FRET efficiency measurements. However, subsequent experimental and theoretical studies have called into question this picture of a polyproline peptide as a "rigid rod". Further studies using terahertz spectroscopy and density functional theory calculations highlighted that polyproline is in fact much less rigid than originally thought. Interconversions between the PPII and PPI helix forms of poly-proline are slow, due to the high activation energy of X-Pro cis-trans isomerization (Ea ≈ 20 kcal/mol); however, this interconversion may be catalyzed by specific isomerases known as prolyl isomerases or PPIases. The interconversion between the PPII and PPI helices involve the cis-trans peptide bond isomerization along the whole peptide chain. Studies based on ion-mobility spectrometry revealed existence of a defined set of intermediates along this process.
Nando's opened its first restaurants within the United Kingdom, in 1992, in the west London suburbs of Ealing and Earls Court, initially focusing on takeaway food. The UK arm, owned by the Enthoven family via a private equity company, struggled until chairman Dick Enthoven put his son Robert in control. The focus then moved from takeaways to a mixed-service (counter ordering and table service) model. This decision was taken after Nando's partnered with Harrison, a branding and design agency. They also advised Nando's to design each restaurant individually so no two restaurants were the same, a brand characteristic of the chain. In 2013, the company employed around 8,000 staff in the UK and had over 280 branches, with about 60 serving food conforming with Islamic dietary laws. In 2010, Nando's UK won the Sunday Times's 'best place to work' award in the big company category. Its sauces and marinades were also retailed in UK supermarkets. Nando's claims to have the largest collection of South African art in the UK, with over 5,000 works displayed in restaurants; original artworks are commissioned by the company. In March 2020, all of Nando's UK restaurants closed temporarily due to nationwide lockdown rules introduced by the government to limit the spread of COVID-19. In late April 2020, Nando's reopened select locations for delivery and collection services, with many more locations opening throughout May. In early July 2020, the restaurant chain started reopening a few of its outlets for eat-in service.
Adopted the American Experience table at its sixth convention in Buffalo, New York, in September 1920, but it wasn't until 1923 that it was actuarially sound. Headquarters in Scranton. Local groups are called "branches", and regional groups are called "Districts". National convention meets quadrennially. 20,000 members in 1930, 32,142 in 247 branches in the mid-1960s, and 31,649 in 210 branches in 1979. 30,000 members in 1994. No ritual or secrecy, but there is a pledge. Open to both sexes 16 and up. The 1979 constitution didn't say anything about Polish ancestry. Purchased Sponjnia Farm in 1929 in Waymart, Pennsylvania, and developed it into a home for aged and sick members. Began Warsaw Village in Thornhurst Township, Pennsylvania, in 1948 as summer vacation area. Helped fund Church of Our Lady of Perpetual Help near Zarki, Poland. Their first constitution declared "Religious, political and social convictions may not hinder admission", but has nevertheless been tied to the Polish National Catholic Church. Polish Roman Catholic Union of America Polish Union of America - Founded in 1890. 10,000 members in 1979. 9,000 in 1994. Active in anti-defamation campaigns, provides scholarships, contributes to churches, charities, and educational foundations; also sponsors radio broadcast. Maintains library, museum, speakers bureau, ethnic awareness programs, and vocational placement services. Also runs White Eagle Young Adults Club.
== History == Although genetics has its roots back in the 19th century with the work of the Bohemian monk Gregor Mendel and other pioneering scientists, human genetics emerged later. It started to develop, albeit slowly, during the first half of the 20th century. Mendelian (single-gene) inheritance was studied in a number of important disorders such as albinism, brachydactyly (short fingers and toes), and hemophilia. Mathematical approaches were also devised and applied to human genetics. Population genetics was created. Medical genetics was a late developer, emerging largely after the close of World War II (1945) when the eugenics movement had fallen into disrepute. The Nazi misuse of eugenics sounded its death knell. Shorn of eugenics, a scientific approach could be used and was applied to human and medical genetics. Medical genetics saw an increasingly rapid rise in the second half of the 20th century and continues in the 21st century.
Sources: en.wikipedia.org
State and local programs are not permitted to participate. The failure to share data has caused foreign governments to refuse donations of expired medications. One exception occurred during the 2010 Swine Flu Epidemic when the FDA authorized expired Tamiflu based on SLEP Data. The SLEP discovered that drugs such as Cipro remained effective nine years after their shelf life, and, as a cost-saving measure, the US military routinely uses a wide range of SLEP tested products past their official shelf life if drugs have been stored properly.
== Interpretation == One interpretation of the art is that humans have the power to destroy nature anywhere; not only in art galleries, but putting this choice in an art gallery makes that power more visible.
=== February–April 1881 === On 14 February Carrington captured Ramokoatsi, which overlooked the main road to Morija. The following day, a force of 370 cavalry, 100 infantry, 50 native levies, and three artillery pieces under Brabant was sent out in search of a new camping ground. Upon crossing a spruit in the Ramibidikwa area, a CMR scout reported a massed formation of Basuto horsemen. Brabant ordered his soldiers to form a square; soon afterwards the Basuto commenced an attack on its front and two flanks. A combination of rifle and case shot fire kept the Basuto at bay in the center and the right flank. On the left, the Basuto managed to almost reach melee range before being likewise driven off. The artillery continued to fire on the retreating Basuto, who suffered 138 casualties in the engagement. One month later Clarke assumed personal command of the force, moving the camp to Ramibidikwa, 20 miles (32 km) from Morija. On 22 March, Carrington was heavily wounded in the vicinity of the new camp. By early April, Sprigg's conduct of the war was being heavily criticized in the Cape Parliament, whose opposition members were pushing for a vote of no confidence. Using Letsie as an intermediary, Robinson organized a meeting between Griffith and Lerotholi outside Maseru on 17 April. The two sides signed an armistice, although Lerotholi was unwilling to surrender his weapons, as the motion would be too unpopular among his tribesmen. On 29 April, Robinson announced the peace settlement, known as the Award.
splicing Any natural or artificial process involving the excision of oligonucleotide sequences from nucleic acid molecules (either DNA or RNA) or of peptide sequences from proteins and the subsequent re-ligation of the flanking fragments into a single continuous molecule lacking the excised sequence. RNA splicing in particular is an important form of post-transcriptional processing whereby introns are removed from primary mRNA transcripts and the exons rejoined (and sometimes rearranged) to create mature mRNAs; a similar process also occurs with the removal of inteins and the rejoining of exteins in the post-translational modification of certain proteins. The term may also refer more generally to artificial techniques for creating recombinant sequences in genetic engineering.
=== Committee assignments === Committee on Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Subcommittee on Commerce, Justice, Science, and Related Agencies Subcommittee on Energy and Water Development Subcommittee on Financial Services and General Government Committee on Banking, Housing, and Urban Affairs Subcommittee on Economic Policy Subcommittee on Financial Institutions and Consumer Protection Subcommittee on Housing, Transportation, and Community Development Committee on the Budget Committee on the Judiciary Subcommittee on Border Security and Immigration Subcommittee on Crime and Terrorism Subcommittee on Privacy, Technology and the Law Subcommittee on Intellectual Property Committee on Small Business and Entrepreneurship
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.